Interactions You Should Know About
1 Funfstuck R, Straube E, Schildbach O, et al. Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection [in German]. Med Klin . 1997;92:574-581.
2 Funfstuck R, Straube E, Schildbach O, et al. Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection [in German]. Med Klin . 1997;92:574-581.
3 Neuvonen PJ, Tokola O, Toivonen ML, et al. Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. Int J Clin Pharmacol Ther Toxicol . 1985;23:497-500.
4 Smythies JR, Halsey JH. Treatment of Parkinson's disease with L-methionine. South Med J. 1984;77:1577.
5 Meininger V, Flamier A, Phan T, et al. L-methionine treatment of Parkinson's disease: preliminary results [in French]. Rev Neurol (Paris). 1982;138:297-303.
6 Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med. 1984;310:483-488.
7 Toborek M, Hennig B. Is methionine an atherogenic amino acid? J Opt Nutr . 1994;3:80-83.
8 Van Brummelen R, du Toit D. L-methionine as immune supportive supplement: a clinical evaluation. Amino Acids . 2006 Sep 29 [Epub ahead of print]
- Reviewer: EBSCO CAM Review Board
- Review Date: 09/2014 -
- Update Date: 09/18/2014 -
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
Copyright © EBSCO Publishing
All rights reserved.